Tomkin Gerald H, Owens Daphne
a Diabetes Institute of Ireland , Beacon Clinic and Trinity College , Dublin 2 , Ireland.
Expert Opin Investig Drugs. 2017 May;26(5):603-617. doi: 10.1080/13543784.2017.1315407. Epub 2017 Apr 13.
Cardiovascular morbidity and mortality are of increasing concern, not only to patients but also to the health care profession and service providers. The preventative benefit of treatment of dyslipidaemia is unquestioned but there is a large, so far unmet need to improve clinical outcome. There are exciting new discoveries of targets that may translate into improved clinical outcome. Areas covered: This review highlights some new pathways in cholesterol and triglyceride metabolism and examines new targets, new drugs and new molecules. The review includes the results of recent trials of relatively new drugs that have shown benefit in cardiovascular endpoint outcomes, drugs that have been licenced without endpoint trials yet available and new drugs that have not yet been licenced but have produced exciting results in animal studies and some in early phase 2 human studies. Expert opinion: The new areas that have been discovered as the cause of dyslipidaemia have opened up a host of new targets for new drugs including antisense RNA's, microRNA's and human monoclonal antibodies. The plethora of new targets and new drugs has made it an extraordinarily exciting time in the development of therapeutics to combat atherosclerosis.
心血管疾病的发病率和死亡率不仅受到患者的日益关注，也引起了医疗行业和服务提供者的关注。血脂异常治疗的预防益处是毋庸置疑的，但目前仍有很大的未满足需求，即改善临床结局。有一些令人兴奋的新靶点发现，可能会转化为更好的临床结局。涵盖领域：本综述重点介绍了胆固醇和甘油三酯代谢的一些新途径，并研究了新靶点、新药和新分子。该综述包括近期相对新药试验的结果，这些新药在心血管终点结局方面显示出益处；已获许可但尚无终点试验的药物；以及尚未获许可但在动物研究和一些2期早期人体研究中产生了令人兴奋结果的新药。专家观点：作为血脂异常病因被发现的新领域为新药开辟了许多新靶点，包括反义RNA、微小RNA和人单克隆抗体。大量的新靶点和新药使得治疗动脉粥样硬化的药物研发进入了一个极其令人兴奋的时期。
